Search hospitals > Kentucky > Louisville
Norton Cancer Institute
Claim this profileLouisville, Kentucky 40202
Global Leader in Lymphoma
Global Leader in Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Leukemia
220 reported clinical trials
13 medical researchers
Summary
Norton Cancer Institute is a medical facility located in Louisville, Kentucky. This center is recognized for care of Lymphoma, Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Leukemia and other specialties. Norton Cancer Institute is involved with conducting 220 clinical trials across 174 conditions. There are 13 research doctors associated with this hospital, such as John Hamm, MD, Don Stevens, MD, Jaspreet Grewal, MD, and Joseph Maly.Area of expertise
1Lymphoma
Global LeaderMYC positive
BCL2 positive
BCL6 positive
2Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
John Hamm, MDNorton Cancer Institute1 year of reported clinical research
Expert in Non-Small Cell Lung Cancer
Studies Cancer
23 reported clinical trials
43 drugs studied
Don Stevens, MDNorton Cancer Institute1 year of reported clinical research
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
24 reported clinical trials
44 drugs studied
Jaspreet Grewal, MDNorton Cancer Institute3 years of reported clinical research
Studies Head and Neck Cancers
Studies Oral Squamous Cell Carcinoma
9 reported clinical trials
14 drugs studied
Joseph MalyNorton Cancer Institute3 years of reported clinical research
Studies Lymphoma
Studies Leukemia
9 reported clinical trials
19 drugs studied
Clinical Trials running at Norton Cancer Institute
Non-Hodgkin's Lymphoma
Lymphoma
B-Cell Lymphoma
Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Peripheral T-Cell Lymphoma
1A46 Injection
for Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).
Recruiting1 award Phase 1 & 2
REGN5837 + Odronextamab
for Aggressive B-Cell Lymphoma
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2 for the combination. The study is focused on patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs). The study is looking at several other research questions, including: What side effects may happen from taking the study drugs How much study drug is in your blood at different times Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects) To find out how well the study drugs work against relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs)
Recruiting1 award Phase 1
Nanatinostat + Valganciclovir
for EBV-Positive Lymphoma
This study is evaluating whether a drug called nanatinostat can be used to treat people with EBV-positive lymphomas.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Norton Cancer Institute?
Norton Cancer Institute is a medical facility located in Louisville, Kentucky. This center is recognized for care of Lymphoma, Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Leukemia and other specialties. Norton Cancer Institute is involved with conducting 220 clinical trials across 174 conditions. There are 13 research doctors associated with this hospital, such as John Hamm, MD, Don Stevens, MD, Jaspreet Grewal, MD, and Joseph Maly.